MSC: A Protein Targeted for Drug Development and Biomarker Use

Target Name: MSC

NCBI ID: G9242

Content of Review Report on MSC Target / Biomarker

MSC

MSC: A Protein Targeted for Drug Development and Biomarker Use

MSC (MUSCULAR SKELETAL CHORD) is a protein that is expressed in various tissues of the body, including muscle, tendon, and bone. It is a unique protein that is responsible for the maintenance and growth of bone and muscle tissue. MSC has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The MSC protein is composed of multiple domains, including a N-terminal alpha-helix, a beta-sheet, and a C-terminal terminal domain. The N-terminal domain is responsible for the protein's ability to interact with various signaling molecules, such as TGF-beta and Wnt. The beta-sheet domain is the most abundant domain in MSC and is responsible for the protein's structural stability and functions as a scaffold. The C-terminal domain is responsible for the protein's ability to interact with other proteins and for its role in the regulation of cellular processes, such as cell adhesion and migration.

MSC has been shown to play a role in the development and maintenance of various diseases. For example, MSC has been shown to contribute to the development of cancer, including breast and colorectal cancers. Additionally, MSC has been shown to contribute to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. MSC has also been shown to contribute to the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Due to its potential as a drug target, MSC has become a focus of research in recent years. Researchers have identified several potential drug candidates that can be targeted to different aspects of the MSC protein. One of the most promising drug candidates is CRISPR/Cas9 , a gene editing tool that can be used to knockdown or activate specific genes, including those responsible for MSC.

Another promising drug candidate is the small molecule inhibitor, SM-301, which targets the protein NG2 and is used to treat various cancers. SM-301 has been shown to be effective in treating various cancers, including breast, lung, and ovarian cancers.

In addition to drug candidates, MSC has also been used as a biomarker for various diseases. For example, MSC has been used as a biomarker for cancer, including breast and colorectal cancers. Additionally, MSC has been used as a biomarker for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

In conclusion, MSC is a protein that plays a critical role in the development and maintenance of various diseases. Its unique structure and various functions make it an attractive target for drug development. The use of MSC as a biomarker for various diseases also makes it an important tool in the diagnosis and treatment of these diseases. Further research is needed to fully understand the role of MSC in diseases and to identify effective drug candidates and biomarkers for these diseases.

Protein Name: Musculin

Functions: Transcription repressor capable of inhibiting the transactivation capability of TCF3/E47. May play a role in regulating antigen-dependent B-cell differentiation

The "MSC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets